Since 2018, in collaboration with various pharmaceutical companies, we have rolled out the clinical version of the ECG device and patient management systems to over 5,000 primary medical institutions, predominantly clinics, across more than 20 provinces nationwide. By March 2019, backend statistics indicated promising outcomes from the installation of these devices. The consistent usage rate of the deployed devices has reached 65%. Notably, clinics with over 100 screenings constitute more than 15% of these figures.

It is anticipated that by the conclusion of 2019, the network of clinics connected through the Heartpal ECG Device will exceed 10,000. Through our services targeting patients at the grassroots level, we aspire to make a meaningful contribution towards reducing fatalities stemming from delayed interventions for myocardial infarctions in rural regions.